We are excited to announce the settlement of this class action lawsuit.   The case involved alleged pay-for-delay antitrust violations by various defendants.  Plaintiffs alleged that Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Zetia and that Defendants’ alleged conduct caused third-party payors to pay too much for branded and generic Zetia in select states.  The Court has preliminarily approved the proposed settlement, which will provide for the payment of $70,000,000.00 to resolve the end-payor claims against them.  The full text of the proposed settlement agreement is available here.